$EQ

Zedelmayer Christine sold $43K of EQ

Zedelmayer Christine (Sr. Vice President and COO) sold 14,584 shares of Equillium, Inc. (EQ) at $2.93 on 2026-06-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Zedelmayer Christine
Published Jun 5, 2026, 8:42 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 5, 2026, 8:48 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$EQ
Neutral
medium confidence
Mentioned
$EQ
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EQNeutralLow
01

Why it matters

The disclosure updates the record of insider ownership and may marginally influence sentiment, but it does not provide new operational or financial information.

02

Market read

A same-day officer sale under a pre-arranged 10b5-1 plan is generally low-signal for trading, with limited expected price impact.

03

What to watch

10b5-1 plans are often routine for liquidity/tax; without context on prior sales frequency or total stake changes, directional inference is weak.

Relevance 6/10Novelty 3/10Timing: Filed same day as the sale (2026-06-05)

Background

The article is an SEC Form 4 insider transaction disclosure for Equillium, Inc.

Company-level read

Ticker impact

$EQNeutralMedium confidence
Context

Equillium COO sold 14,584 shares in an open-market transaction disclosed via SEC Form 4 on 2026-06-05.

Expected impact

Likely limited/short-lived impact; any move would be small unless accompanied by unusual volume or additional disclosures.

Evidence & confidence

The filing is an officer sale (not a buy) but explicitly states a pre-arranged Rule 10b5-1 plan, which reduces interpretive weight.

Market effects

Minimal; this is company-specific insider activity with no stated sector/regulatory trigger.

None indicated.

None indicated.

Counterpoint

If the sale size is unusually large relative to prior patterns, it could still be interpreted as a sentiment headwind despite 10b5-1.

Key entities

  • Equillium, Inc.

    Subject of the SEC Form 4 insider sale by its COO.

  • Zedelmayer Christine

    Sr. Vice President and COO who sold shares under a Rule 10b5-1 plan.

Related articles

$EQMedAI 8/10

Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1

Equillium (NASDAQ:EQ) presented preclinical data linking aryl hydrocarbon receptor (AhR) activation to miR-124 induction, led by CSO Stephen Connelly. Using its AhR modulator EQ504 and Abivax’s obefazimod (ABX464), the company reported miR-124 induction in immune cells with AhR antagonism reducing it, alongside decreases in pro-inflammatory cytokines. ABX464 showed an AhR EC50 ~400 nM in reporter assays. Equillium said Phase 1 readouts will focus on colon tissue drug exposure (EC50–EC90) and CYP